KALARIS THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
KALARIS THERAPEUTICS, INC. (KLRS) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $2.67 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-08-11
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $2.67M.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $4.63M.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $9.55M.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $5.87M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value |
|---|---|
| 2026-06-30 | $2.67M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $4.63M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $9.55M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $5.87M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $2.13M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $44.66M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $20.16M 10-Q · filed 2025-11-12 |
| 2023-06-30 | $19.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $46.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $786.00K 10-K · filed 2024-03-15 |
| 2022-09-30 | $3.68M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $44.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $181.00K 10-Q · filed 2022-05-05 |
| 2021-12-31 | $480.00K 10-K · filed 2023-02-15 |
| 2021-09-30 | $31.56M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $11.26M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $24.62M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $81.82M 10-K · filed 2022-02-10 |
| 2020-09-30 | $39.55M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |